Narjust Florez: We don’t have to fit in anybody’s box
Narjust Florez shared a post by Dana-Farber News on X/Twitter, adding:
”Once, I was told that my career pathway wouldn’t get me anywhere.
- ‘I needed to be this…’
- ‘I should do that…’
We don’t have to fit in anybody’s box…
<5 years from fellowship.”
Quoting Dana-Farber News‘s post:
”Congratulations to Narjust Florez who has been named a Fellow of the American Society of Clinical Oncology (FASCO). Narjust Florez is the Associate Director of the Cancer Care Equity Program and a thoracic medical oncologist at Dana Farber.”
Source: Narjust Florez/X and Dana-Farber News/X
Narjust Florez is the Associate Director of the Cancer Care Equity Program and a thoracic medical oncologist at the Dana-Farber Brigham Cancer Center. She is the principal investigator of the Sexual Health Assessment in Women with Lung Cancer (SHAWL) Study, the largest study to date evaluating sexual dysfunction in women with lung cancer. She received the 2020 Rising Star award by the LEAD National Conference for women in hematology and oncology. In addition, Dr. Florez founded the Florez Lab in 2019. The laboratory focuses on lung cancer, social justice issues in medicine, and medical education.
Dana-Farber Cancer Institute, located in Boston, Massachusetts, is a leading institution for cancer treatment and research. It was founded by Sidney Farber on 1947. Currently, the Institute has over 5,000 staff, faculty, and clinicians on board. They manage in excess of 640,000 outpatient visits each year, oversee more than 1,000 hospital discharges annually, and are actively involved in over 1,100 ongoing clinical trials.
As of 2023, Dana-Farber is ranked as the #4 cancer hospital globally. Dana-Farber’s research contributions include the development of Gleevec, a highly successful treatment for chronic myeloid leukemia.